Marija Zivanovic

Marija Zivanovic

Auto-generated profile, based on publicly available information

Marija Zivanovic

Department of Molecular Oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of the Serbian Chemical Society
Verified
Journal Article
Open access
PDF file
MZMarija Zivanovic
Marija Zivanovic
LALjubodrag Aleksić
Ljubodrag Aleksić
MSMilica Selakovic
Milica Selakovic
ADAna Djuric
Ana Djuric
MCMilkica Crevar
Milkica Crevar
TSTatjana Srdic-Rajic
Tatjana Srdic-Rajic
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer marked by oxidative stress, metabolic rewiring, and resistance to cell death. Ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, represents a promising therapeutic vulnerability in PDAC; however, intrinsic resistance to ferroptosis limits its therapeutic exploitation. This study shows that 4-aminoquinoline derivatives sensitize PDAC cell lines (MIA PaCa-2 and PANC-1) to erastin-induced ferroptotic cell death. Ferroptosis sensitization occurred independently of caspase-3/7 activation and was associated with increased ROS production, mitochondrial oxidative stress, lipid peroxidation, and redox imbalance. Importantly, sensitivity to ferroptosis was accompanied by decreased GSH levels, reduced intracellular cystine levels, and differential regulation of the KEAP1-Nrf2-p62 axis. While PANC-1 cells exhibited enhanced oxidative stress and KEAP1 upregulation, MIA PaCa-2 cells maintained relative redox homeostasis unless exposed to combined treatment conditions. To our knowledge, this study provides the first evidence that 4- aminoquinoline derivatives promote sensitization to ferroptosis in PDAC and highlights the therapeutic potential of targeting redox metabolism and stress-adaptive signaling to overcome resistance to therapy in pancreatic cancer.